

Petri Bono

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9078422/publications.pdf>

Version: 2024-02-01

68
papers

4,257
citations

257450

24
h-index

118850

62
g-index

69
all docs

69
docs citations

69
times ranked

6702
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102054.	1.6	14
2	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Cells</i> , 2022, 11, 17.	4.1	7
3	Modelling treatment benefit for bexmarilimab (an anti-Cleaver-1 antibody and a novel macrophage) Tj ETQq1 1 0.784314 rgBT /Overlo e14500-e14500.	1.6	0
4	Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2645-2645.	1.6	2
5	Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4205-4220.	7.0	29
6	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. <i>Modern Pathology</i> , 2021, 34, 2229-2241.	5.5	25
7	ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 63-70.	3.1	7
8	Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. <i>ESMO Open</i> , 2020, 5, e001081.	4.5	6
9	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1730-1736.	6.4	63
10	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e526-e533.	1.9	9
11	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	1.6	185
12	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	3.7	22
13	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2019, 108, 33-40.	2.8	96
14	Cancer costs and outcomes for common cancer sites in the Finnish population between 2009â€“2014. <i>Acta OncolÃ³gica</i> , 2018, 57, 983-988.	1.8	6
15	Modularising outpatient care delivery: A mixed methods case study at a Finnish University Hospital. <i>Health Services Management Research</i> , 2018, 31, 195-204.	1.7	6
16	p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. <i>Clinical Cancer Research</i> , 2018, 24, 3046-3052.	7.0	8
17	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naÃ“ve and CYP17 Inhibitor-naÃ“ve Patients: Follow-up from the ARADES and ARAFOR Trials. <i>European Urology Focus</i> , 2018, 4, 547-553.	3.1	30
18	Cancer costs and outcomes in the Finnish population 2004â€“2014. <i>Acta OncolÃ³gica</i> , 2018, 57, 297-303.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.. Journal of Clinical Oncology, 2018, 36, 414-414.	1.6	10
20	Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL study).. Journal of Clinical Oncology, 2018, 36, 4574-4574.	1.6	0
21	Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 4561-4561.	1.6	0
22	Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 384-390.e3.	1.9	14
23	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. JAMA Oncology, 2017, 3, 793.	7.1	74
24	Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 487-494.	1.9	16
25	Safety and Antitumor Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. European Urology Focus, 2017, 3, 606-614.	3.1	18
26	Novel Angiogenesis Markers as Long-Term Prognostic Factors in Patients With Renal Cell Cancer. Clinical Genitourinary Cancer, 2017, 15, e15-e24.	1.9	5
27	Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.. Journal of Clinical Oncology, 2017, 35, 9520-9520.	1.6	188
28	ODM-204 a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 246-246.	1.6	0
29	Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer. Clinical Genitourinary Cancer, 2016, 14, e283-e289.	1.9	9
30	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. Scandinavian Journal of Urology, 2016, 50, 380-386.	1.0	12
31	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 1590-1598.	10.7	594
32	Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. European Urology, 2016, 69, 834-840.	1.9	49
33	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 883-895.	10.7	1,091
34	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clinical Genitourinary Cancer, 2016, 14, 406-414.	1.9	8
35	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology, 2016, 34, 244-250.	1.6	174
36	Sunitinib-induced hypertension, neutropaenia and thrombocytopenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU International, 2016, 117, 110-117.	2.5	47

#	ARTICLE	IF	CITATIONS
37	Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.. Journal of Clinical Oncology, 2016, 34, 1001-1001.	1.6	3
38	Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours.. Journal of Clinical Oncology, 2016, 34, 2576-2576.	1.6	3
39	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. Journal of Clinical Oncology, 2016, 34, 4010-4010.	1.6	50
40	Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.. Journal of Clinical Oncology, 2016, 34, 4501-4501.	1.6	36
41	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 498-498.	1.6	21
42	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. Journal of Clinical Oncology, 2016, 34, 6-6.	1.6	33
43	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0153745.	2.5	20
44	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast, 2015, 24, 182-190.	2.2	44
45	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	10.7	108
46	Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial.. Journal of Clinical Oncology, 2015, 33, 10505-10505.	1.6	8
47	Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.. Journal of Clinical Oncology, 2015, 33, 230-230.	1.6	2
48	Correlation of endothelial angiopoietin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 461-461.	1.6	0
49	VEGFR3 and CD31 as prognostic factors in renal cell cancer. Anticancer Research, 2015, 35, 921-7.	1.1	13
50	A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. OncoTargets and Therapy, 2014, 7, 1177.	2.0	2
51	Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer. Oncology Letters, 2014, 7, 553-559.	1.8	1
52	Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. Journal of Clinical Oncology, 2014, 32, 1412-1418.	1.6	381
53	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology, The, 2014, 15, 975-985.	10.7	172
54	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.. Journal of Clinical Oncology, 2014, 32, 5079-5079.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3114-TPS3114.	1.6	10
56	A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 115-115.	1.6	3
57	ODM-201 and the CNS: A clinical perspective.. Journal of Clinical Oncology, 2014, 32, 275-275.	1.6	4
58	Principal: A prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib.. Journal of Clinical Oncology, 2014, 32, TPS4600-TPS4600.	1.6	0
59	A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.. Journal of Clinical Oncology, 2013, 31, TPS4592-TPS4592.	1.6	1
60	Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. Journal of Clinical Oncology, 2012, 30, 11-18.	1.6	114
61	Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.. Journal of Clinical Oncology, 2012, 30, 507-507.	1.6	10
62	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)â€”PISCES study, NCT 01064310.. Journal of Clinical Oncology, 2012, 30, CRA4502-CRA4502.	1.6	18
63	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)â€”PISCES study, NCT 01064310.. Journal of Clinical Oncology, 2012, 30, CRA4502-CRA4502.	1.6	27
64	Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol, 2011, 50, 569-573.	1.8	63
65	Reply to M. Isik et al. Journal of Clinical Oncology, 2010, 28, e335-e336.	1.6	0
66	Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology, The, 2009, 10, 1145-1151.	10.7	65
67	High LYVE-1â€”Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer. Clinical Cancer Research, 2004, 10, 7144-7149.	7.0	156
68	Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer, 2003, 97, 2767-2775.	4.1	52